血液系统恶性肿瘤中FDG-PET/CT的变异与陷阱
本文综述血液系统恶性肿瘤中[18F]FDG-PET/CT判读的变异与陷阱,指出扫描方案和图像重建方法不一致可影响视觉与定量判读,且FDG摄取并非仅反映恶性病灶的葡萄糖消耗,炎症、感染、良性肿瘤、反应性胸腺增生、组织细胞浸润及粒细胞集落刺激因子治疗、放疗、化疗或手术后均可致假阳性或假阴性,核医学医师需熟悉正常分布与常见干扰表现。
要点
- 扫描方案与图像重建方法不一致可损害PET/CT视觉和定量判读的可靠性。
- FDG摄取也见于炎症、感染、良性肿瘤、反应性胸腺增生及组织细胞浸润等情况。
- 粒细胞集落刺激因子治疗、放疗、化疗或手术后FDG摄取可干扰判读。
核心结论
- 核医学医师需熟悉[18F]FDG的正常分布及常见干扰表现,以避免误判并影响患者管理。
研究设计与样本
- 本文为综述,描述血液系统恶性肿瘤中[18F]FDG-PET/CT判读的多种变异与陷阱。
主要发现
- 扫描方案和图像重建方法不一致可损害PET/CT视觉与定量判读的可靠性。
- FDG摄取不仅反映恶性病灶的组织葡萄糖消耗,也见于炎症病灶、局部和全身感染、良性肿瘤、反应性胸腺增生及组织细胞浸润等。
- 粒细胞集落刺激因子治疗、放疗、化疗或手术干预后FDG摄取也是假阳性或假阴性判读的潜在来源。
临床怎么用
- 判读时需结合正常FDG分布及上述常见干扰表现,正确识别并尽可能解释变异与陷阱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematologic malignancies represent a vast group of hematopoietic and lymphoid cancers that typically involve the blood, the bone marrow, and the lymphatic organs. Due to extensive research and well defined and standardized response criteria, the role of [18F]FDG-PET/CT is well defined in these malignancies. Never the less, the reliability of visual and quantitative interpretation of PET/CT may be impaired by several factors including inconsistent scanning protocols and image reconstruction methods. Furthermore, the uptake of [18F]FDG not only reflects tissue glucose consumption by malignant lesions, but also in other situations such as in inflammatory lesions, local and systemic infections, benign tumors, reactive thymic hyperplasia, histiocytic infiltration, among others; or following granulocyte colony stimulating factors therapy, radiation therapy, chemotherapy or surgical interventions, all of which are a potential source of false-positive or negative interpretations. Therefore it is of paramount importance for the Nuclear Medicine Physician to be familiar with, not only the normal distribution of [18F]FDG in the body, but also with the most frequent findings that may hamper a correct interpretation of the scan, which could ultimately alter the patients management. In this review, we describe these myriad of situations so the interpreting physician can be familiar with them, providing tools for their correct identification and interpretation when possible.
引用
- Pilkington P, Lopci E, Adam JA, et al. FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. Semin Nucl Med. 2021. PMID: 34272037. doi:10.1053/j.semnuclmed.2021.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。